These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention

These firms are very niche but growing steadily and have Ebos CEO John Cullity's attention
Ebos chief executive John Cullity says shareholders can expect more buying in Southeast Asia. (Image: Ebos)
Rebecca Stevenson
Listed healthcare and pet company Ebos says it sees investment potential in regenerative medicine firm Origin Biologics. Dual-listed Ebos reported its full-year result on Wednesday, with sales revenue exceeding A$13.2 billion (NZ$14.4b) for the first time. Ebos is known for its canny acquisitions and chief executive John Cullity said the company would continue its foray into Southeast Asia and medical devices, but there were also opportunities in the US. Ebos completed a major acquisition in 2022 when it purchased Lifehealthcare,...

More Markets

NZ sharemarket rises on back of positive news
Markets Market close

NZ sharemarket rises on back of positive news

The S&P/NZX 50 Index closed at 13,041.9, rising 276.66 points or 2.17%

Graham Skellern 22 Nov 2024
Oceania shrinks footprint, prioritises balance sheet
Property

Oceania shrinks footprint, prioritises balance sheet

Oceania has divested four aged care facilities in the space of six months.

Gregor Thompson 22 Nov 2024
The Warehouse’s plan to come back ‘with a vengeance’
Retail

The Warehouse’s plan to come back ‘with a vengeance’

Executives face tough questions at the retailer’s AGM.

Victoria Young 22 Nov 2024
Wellington's blue sky boondoggle
Infrastructure

Pattrick Smellie: Wellington's blue sky boondoggle

Is the capital's airport serious, or is Infratil just trying to pump value?

Pattrick Smellie 22 Nov 2024